<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915629</url>
  </required_header>
  <id_info>
    <org_study_id>2008-A01513-52</org_study_id>
    <nct_id>NCT00915629</nct_id>
  </id_info>
  <brief_title>Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>PiLeJe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioFortis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Larena SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vulvovaginal candidiasis (VVC) is a common infection among women that is associated with&#xD;
      considerable morbidity and health-care cost. 75% of women will suffer of Candida infection&#xD;
      for at least one time in their life. 20% of women who suffer from VVC will have ≥ 4 episodes&#xD;
      of VVC during the one year prior to the survey. 80% of these VVC are caused by Candida&#xD;
      albicans. Current treatments, based on imidazoles, face many failures or recurrences. The&#xD;
      type of probiotic Lactobacillus may participate in the prevention of recurrent&#xD;
      vulvo-vaginitis in reducing the proliferation of intestinal Candida albicans, its adherence&#xD;
      to the vaginal walls, the potentiation of its propagation. The primary objective of this&#xD;
      study was to investigate if our supplementary treatment could improve the initial cure rate&#xD;
      after vaginal econazole therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study was to investigate if Lactibiane candisis 5M supplementation could lengthen the time to relapse after initial local cure</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective of this study is to compare the number of recurrence in the lactibiane candisis 5M group versus placebo.</measure>
    <time_frame>2, 3, 6 and 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Vaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactibiane candisis 5M</intervention_name>
    <description>2 gelules per day for 2 months then 1 gelule per day for 4 months</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women&#xD;
&#xD;
          -  18-65 years&#xD;
&#xD;
          -  suffering from 4 or more episodes of VVC during the 1 year prior to the survey&#xD;
&#xD;
          -  all participants must be symptomatic with a microbiological proof of infection with&#xD;
             candida albicans&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, lactation being&#xD;
&#xD;
          -  HIV infection, chemotherapy or illness serious enough to induce an immune deficiency.&#xD;
             A diabetic patient will not be systematically excluded;&#xD;
&#xD;
          -  Vulvo-vaginitis and / or cervicitis specific, defined in a bacteriological examination&#xD;
             by the presence of herpes virus, gonorrhea or chlamydia;&#xD;
&#xD;
          -  Bacterial Vaginosis or Trichomonas;&#xD;
&#xD;
          -  Use of vaginal probiotics in the months before inclusion;&#xD;
&#xD;
          -  Cure of probiotics in the months preceding the inclusion;&#xD;
&#xD;
          -  Contraindication to Gynopévaryl LP&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AZOULAY Catherine, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Pileje</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

